The role of oral antiviral therapy in hepatitis B-related hepatocellular carcinoma

Abstract

Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma (HCC) in places where chronic hepatitis B infection is endemic. Oral nucleos(t)ide analog (NA) therapy can reduce the risk of HCC, but cannot completely prevent its development. For HBV-related HCCs, viral inhibition by NAs can preserve or improve liver function, thereby increasing the chance of therapeutic intervention. After surgical resection, NAs can prevent reactivation of HBV, and also reduce the chance of de novo development of HCC in the remnant liver. For those who undergo liver transplantation, NAs are essential to prevent reactivation and graft hepatitis, but is not likely to prevent HCC recurrence, which is due to metastatic disease. The role of NAs for non-curable advanced HCC is less well defined. These include patients undergoing locoregional therapy, chemotherapy, or palliation. Although antiviral therapy can preserve liver function, which may be compromised by HBV, it is unable to prevent disease progression from HCC. At the time of HCC diagnosis, most patients will already be receiving NAs, and these patients should be maintained on therapy. For patients not on antiviral therapy at the time of HCC diagnosis, the decision to commence therapy is often determined by the stage of HCC and life expectancy. Patients undergoing curative therapy, or locoregional therapy/chemotherapy with reasonable life expectancy, should be commenced on antiviral therapy.

Keywords

Antiviral therapy / hepatitis B virus / hepatocellular carcinoma

References

[1] Schweitzer A,Mikolajczyk RT,Ott JJ.Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013..Lancet2015;386:1546-55

[2] El-Serag HB.Epidemiology of viral hepatitis and hepatocellular carcinoma..Gastroenterology2012;142:1264-73.e1

[3] Fung J,Yuen MF.Hepatitis B and C virus-related carcinogenesis..Clin Microbiol Infect2009;15:964-70

[4] Levrero M.Mechanisms of HBV-induced hepatocellular carcinoma..J Hepatol2016;64:S84-101

[5] Sung WK,Li S,Liu X,Lee NP,Ariyaratne PN,Mulawadi FH,Liu AM,Fan ST,Gong Z,Lin Z,Zhang Q,Chou WC,Hao K,Zhang C,Buser C,Kan Z,Mao M,Wang J.Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma..Nat Genet2012;44:765-9

[6] Zhang XD,Ye LH.Hepatitis B virus X protein accelerates the development of hepatoma..Cancer Biol Med2014;11:182-90 PMCID:PMC4197427

[7] Peng Z,Gu W,Li D,Qiu G.Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis..Int J Oncol2005;26:467-73

[8] Wang HC,Lai MD.Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis..Cancer Sci2006;97:683-8

[9] Zamarron BF.Dual roles of immune cells and their factors in cancer development and progression..Int J Biol Sci2011;7:651-8

[10] Chen CJ,Su J,You SL,Huang GT.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level..JAMA2006;295:65-73

[11] Chen G,Shen F,London WT.Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study..Am J Gastroenterol2006;101:1797-803

[12] Yang HI,Liaw YF,Sun CA,Hsiao CK,Chen DS.Hepatitis B e antigen and the risk of hepatocellular carcinoma..N Engl J Med2002;347:168-74

[13] Liu D,Wang Y,He J,Fan C,Liu Z,Chen L,Guo D.Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity..Hepatology2016;64:390-404

[14] Tada T,Toyoda H,Tanikawa M,Kanamori A,Yama T.HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics..J Hepatol2016;65:48-56

[15] Seeger C.Molecular biology of hepatitis B virus infection..Virology2015;479–480:672-86 PMCID:PMC4424072

[16] Yang Z,Lu Y,Tang B.Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis..Oncotarget2016;7:12525-36 PMCID:PMC4914302

[17] Kao JH,Lai MY.Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers..Gastroenterology2003;124:327-34

[18] Menendez-Arias L,Pacheco B.Nucleoside/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance..Curr Opin Virol2014;1-9

[19] Seifer M,Colonno R.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir..Antimicrob Agents Chemother1998;42:3200-8 PMCID:PMC106023

[20] Terrault NA,Chang KM,Jonas MM.AASLD guidelines for treatment of chronic hepatitis B..Hepatology2016;63:261-83

[21] European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection..J Hepatol2017;67:370-98

[22] Sarin SK,Lau GK,Chan HL,Chen DS,Chen PJ,Dokmeci AK,Hou JL,Jia J,Lai CL,Lim SG,Locarnini S,Mohamed R,Park J,Sharma BC,Wang FS,Yuen MF,Kao JH.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update..Hepatol Int2016;10:1-98 PMCID:PMC4722087

[23] Liaw YF,Chow WC,Lee CZ,Tanwandee T,Shue K,Dixon JS,Sabbat J.Lamivudine for patients with chronic hepatitis B and advanced liver disease..N Engl J Med2004;351:1521-31

[24] Zhou HY,Chen WD.Hepatitis B virus mutation may play a role in hepatocellular carcinoma recurrence: a systematic review and meta-regression analysis..J Gastroenterol Hepatol2015;30:977-83

[25] Yang J,Zhang H.HBV genotype C strains with spontaneous YMDD mutations may be a risk factor for hepatocellular carcinoma..J Med Virol2014;86:913-7

[26] Yang JH,Chen XB,Wang X.Relationship between hepatocellular carcinoma and hepatitis B virus genotype with spontaneous YMDD mutations..World J Gastroenterol2013;19:3861-5 PMCID:PMC3699046

[27] Chang TT,Wu SS,Han KH,Safadi R,Halota W,Chi YC,Hindes R,Beebe S.Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients..Hepatology2010;52:886-93

[28] Marcellin P,Buti M,Sievert W,Washington MK,Flaherty JF,Bornstein JD,Subramanian GM,Heathcote EJ.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study..Lancet2013;381:468-75

[29] Hosaka T,Kobayashi M,Kawamura Y,Akuta N,Saitoh S,Ikeda K,Kumada H.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection..Hepatology2013;58:98-107

[30] Kim WR,Berg T,Yee LJ,Flaherty JF,Therneau TM,Fung S,Buti M.Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B..Cancer2015;121:3631-8

[31] Wu CY,Ho HJ,Lee TY,Wu C.Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study..Gastroenterology2014;147:143-51.e5

[32] Torzilli G,Kokudo N,Capussotti L,Vauthey JN,De Santibanes E,Morenghi E.A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations? An observational study of the HCC East-West study group..Ann Surg2013;257:929-37

[33] Sasaki K,Nishioka Y,Sugawara T,Hashimoto M.Impact of viral etiology on postoperative de novo recurrence after hepatectomy for hepatocellular carcinoma in cirrhotic patients..J Gastrointest Surg2017;21:487-95

[34] Li Z,Jiang P,Wu G,Zhang X,Han X,Li X.HBV is a risk factor for poor patient prognosis after curative resection of hepatocellular carcinoma: a retrospective case-control study..Medicine (Baltimore)2016;95:e4224 PMCID:PMC4979780

[35] Chen X,Liu Y,Zhu B,Chen W,Wang Y.The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses..Oncotarget2016;7:49299-309 PMCID:PMC5226509

[36] Huang G,Shen F,Fu SY,Zhou WP.Preoperative hepatitis B virus DNA level is a risk factor for postoperative liver failure in patients who underwent partial hepatectomy for hepatitis B-related hepatocellular carcinoma..World J Surg2014;38:2370-6

[37] Hung IF,Lai CL,Fan ST.Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection..Am J Gastroenterol2008;103:1663-73

[38] Wei X,Li S,Guo W,Cheng S.Hepatitis B virus infection and active replication promote the formation of vascular invasion in hepatocellular carcinoma..BMC Cancer2017;17:304 PMCID:PMC5414329

[39] Lao XM,Ye LT,Shi M,Guo R,Li S,Yuan Y.Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma..Liver Int2013;33:595-604

[40] Huang G,Lau WY,Shen F,Fu SY.Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels..Ann Surg2013;257:490-505

[41] Xie ZB,Peng YC,Wang XB,Bai T,Li LQ.Postoperative hepatitis B virus reactivation and surgery-induced immunosuppression in patients with hepatitis B-related hepatocellular carcinoma..J Surg Oncol2015;112:634-42

[42] Qiao M,Burrell CJ.Intracellular factors, but not virus receptor levels, influence the age-related outcome of DHBV infection of ducks..Virology1992;186:517-23

[43] Gong WF,Lu SD,Zhang QM,Zhang ZM,Li LQ.Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma..Oncotarget2017;8:15047-56

[44] Xie ZB,Fu DL,Yang XW.Postoperative hepatitis B virus reactivation in hepatitis B virus-related hepatocellular carcinoma patients with hepatitis B virus DNA levels <500 copies/mL..Onco Targets Ther2016;9:4593-603 PMCID:PMC4966687

[45] Lee JI,Chang HY,Kim JM,Kim YS.Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus..J Gastroenterol Hepatol2014;29:1019-27

[46] Sohn W,Cho JY,Choi GS,Kwon CH,Sinn DH,Choi MS,Koh KC,Yoo BC.Influence of hepatitis B virus reactivation on the recurrence of HBV-related hepatocellular carcinoma after curative resection in patients with low viral load..J Viral Hepat2015;22:539-50

[47] Sohn W,Kim JM,Joh JW,Gwak GY,Lee JH,Paik SW.HBV DNA and HBsAg levels as risk predictors of early and late recurrence after curative resection of HBV-related hepatocellular carcinoma..Ann Surg Oncol2014;21:2429-35

[48] Wu JC,Chau GY,Lai CR,Huo TI,Lee SD.Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma..J Hepatol2009;51:890-7

[49] Lee HW,Kim DY,Kim KS,Ahn SH.Less fibrotic burden differently affects the long-term outcomes of hepatocellular carcinoma after curative resection..Oncology2017;93:224-32

[50] Wei Q,Luo HX,Deng YN,Li H,Yang Y.Better prognosis of hepatic resection combined with antiviral therapy for HBV-related hepatocellular carcinoma with BCLC Stage B/C..Asian J Surg2017;40:453-62

[51] Ho CM,Shau WY,Wu YM.Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities..Surgery2012;151:700-9

[52] Lei Z,Wu D,Wang Q,Wang K,Lau WY,Shen F.Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the milan criteria..JAMA Surg2016;151:356-63

[53] Zhou HB,Zhong ZR,Jiang XL,Wang H,Hu HP.Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load..Am J Cancer Res2015;5:756-71 PMCID:PMC4396049

[54] Huang G,Zhou WP,Pan ZY,Wu MC.Prediction of hepatocellular carcinoma recurrence in patients with low hepatitis B virus DNA levels and high preoperative hepatitis B surface antigen levels..JAMA Surg2014;149:519-27

[55] Hung IF,Poon RT,Chui AH,Fung JY,Yuen JC,Choi O,Yuen MF.Risk factors and post-resection independent predictive score for the recurrence of hepatitis B-related hepatocellular carcinoma..PLoS One2016;11:e0148493 PMCID:PMC4762706

[56] Yin J,Han Y,Deng Y,Guo W,Wang H,Cao G.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study..J Clin Oncol2013;31:3647-55

[57] Wu CY,Ho HJ,Kuo KN,Lin JT.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection..JAMA2012;308:1906-14

[58] Liu GM,Shen SL,Peng BG.Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis..Hepatol Res2016;46:100-10

[59] Huang G,Wang ZG,Yuan SX,Zhou WP.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial..Ann Surg2015;261:56-66

[60] Wong GL,Chan HL,Tsoi KK.Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma..Aliment Pharmacol Ther2016;43:802-13

[61] Zhang H,Yuan G,Yang D.Antiviral therapy improves the survival rate and decreases recurrences and fatalities in liver cancer patients following curative resection: a meta-analysis..Mol Clin Oncol2015;3:1239-47 PMCID:PMC4665680

[62] Zhou Y,Zhao Y,Li B.Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis..World J Surg2014;38:2395-402

[63] Chong CC,Wong VW,Cheung YS,Lee KF,Chan HL.Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study..Aliment Pharmacol Ther2015;41:199-208

[64] Ke Y,You XM,Liang YR,Li LQ.Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy..Cancer Biol Med2013;10:158-64 PMCID:PMC3860342

[65] Huang S,Lei Z,Li J,Wang K,Wan X.Antiviral therapy inhibits viral reactivation and improves survival after repeat hepatectomy for hepatitis B virus-related recurrent hepatocellular carcinoma..J Am Coll Surg2017;224:283-93.e4

[66] Fung J.Managing hepatitis B: before and after liver transplantation..Ind J Transpl2011;5:77-80

[67] Fung J,Yuen MF.Management of chronic hepatitis B in severe liver disease..World J Gastroenterol2014;20:16053-61 PMCID:PMC4239491

[68] Markowitz JS,Conrad AJ,Seu P,Goss JA,Pakrasi A,Murray NG,Holt C,Stribling R.Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin..Hepatology1998;28:585-9

[69] Shouval D.Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review..Hepatology2000;32:1189-95

[70] Gane EJ,Strasser S,Ring J,McCaughan GW.Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation..Gastroenterology2007;132:931-7

[71] Angus PW,Strasser SI,Gane E.A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis..Hepatology2008;48:1460-6

[72] Fung J,Chan SC,Chok KS,Dai WC,Cheung TT,Lam B,Lo CM.Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation..Gastroenterology2011;141:1212-9

[73] Fung J,Cheung C,Chok KS,Chan AC,Seto WK,Lai CL.Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B..Am J Gastroenterol2013;108:942-8

[74] Fung J,Chok K,Cheung TT,Sin SL,Ng K,Seto WK,Fung Yuen M.Long term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years..Hepatology2017;66:1036-44

[75] Fung J,Chok K,Sin SL,Dai WC,Ng K,Seto WK,Yuen MF.Oral nucleos(t)ide analogs alone after liver transplantation in chronic hepatitis B with preexisting rt204 mutation..Transplantation2017;101:2391-8

[76] Campsen J,Trotter J,Freise C,Cameron A,Kam I,Saab S,Emond J,Lukose T,Klintmalm G.Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues..Liver Transpl2013;19:1020-9

[77] Faria LC,Roque-Afonso AM,Roche B,Ferrari TC,Dussaix E,Brechot C.Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation..Gastroenterology2008;134:1890-9; quiz 2155

[78] Llovet JM.Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival..Hepatology2003;37:429-42

[79] Seto WK,Hwang YY,Fung J,Gill H,Lie AK,Kwong YL.Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study..J Clin Oncol2014;32:3736-43

[80] Seto WK.Hepatitis B virus reactivation during immunosuppressive therapy: appropriate risk stratification..World J Hepatol2015;7:825-30 PMCID:PMC4411525

[81] Lao XM,Shi M,Li S,Yuan Y,Li J,Lin X.Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma..Hepatol Res2011;41:553-63

[82] Xu X,Tian H,Ge N,Yang B.Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma..J Gastroenterol Hepatol2014;29:1273-8

[83] Shao W,Cong N,Song J.The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level..Ther Clin Risk Manag2015;11:1367-70 PMCID:PMC4567233

[84] Li X,Chen ZH,Ma XK,Wu DH,Chen J,Lin ZX,Wei L,Lin Q.Efficacy of prophylactic entecavir for hepatitis B virus-related hepatocellular carcinoma receiving transcatheter arterial chemoembolization..Asian Pac J Cancer Prev2015;16:8665-70

[85] Nagamatsu H,Nagaoka S,Matsugaki S,Tajiri N,Koga H,Kumashiro R.Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy..Am J Gastroenterol2004;99:2369-75

[86] Li X,Chen ZH,Wu DH,Ma XK,Wen JY,Wang TT,Lin ZX,Dong M.Hepatitis B virus DNA negativity acts as a favorable prognostic factor in hepatocellular carcinoma patients..Asian Pac J Cancer Prev2014;15:9635-41

[87] Dan JQ,Huang JT,Gao HJ,Xu L.Hepatitis B virus reactivation after radiofrequency ablation or hepatic resection for HBV-related small hepatocellular carcinoma: a retrospective study..Eur J Surg Oncol2013;39:865-72

[88] Sohn W,Lee MW,Lim HK,Gwak GY,Lee JH,Paik SW.Predisposing factors for recurrence of HBV-related small hepatocellular carcinoma after percutaneous radiofrequency ablation..Scand J Gastroenterol2014;49:373-80

[89] Sohn W,Choi SK,Lee MW,Cho JY,Sinn DH,Choi MS,Koh KC,Rhim H.Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma..Oncotarget2016;7:47794-807 PMCID:PMC5216979

[90] Lee TY,Zeng YS,Wu MS.Association between nucleos(t)ide analog and tumor recurrence in hepatitis B virus-related hepatocellular carcinoma after radiofrequency ablation..Hepatology2016;63:1517-27

[91] Yoo SH,Kwon JH,Jang B.Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization..Clin Mol Hepatol2016;22:458-65 PMCID:PMC5266345

[92] Hann HW,Brown D,Rosato E,Hann RS,Dunn S.A long-term study of the effects of antiviral therapy on survival of patients with HBV-associated hepatocellular carcinoma (HCC) following local tumor ablation..Cancer Med2014;3:390-6 PMCID:PMC3987088

[93] He L,Zhao Y,Jiang Y,Yang Z.Efficacy of nucleot(s)ide analogs therapy in patients with unresectable HBV-related hepatocellular carcinoma: a systematic review and meta-analysis..Dis Markers2017;2017:7075935 PMCID:PMC5370486

[94] Nagai H,Matsui D,Kanayama M,Momiyama K,Iida K,Igarashi Y.Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma..Clin Dev Immunol2012;2012:607851 PMCID:PMC3359796

[95] Yang Y,Li J,Yan W,Xia F,Li Q.A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib..Liver Int2015;35:2147-54

[96] Lim S,Kim GM,Choi HJ.Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib..J Gastroenterol Hepatol2015;30:1024-31

[97] Xu L,Huang J,Zhou Z,Li S.Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib..J Gastroenterol Hepatol2015;30:1032-9

[98] Zhang P,Wen F,Fu P.Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib..J Gastroenterol Hepatol2016;31:1978-85

[99] Jackson R,Berhane S,Johnson P.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials..J Clin Oncol2017;35:622-8

[100] Papatheodoridis GV,Dalekos GN,Chi H,Calleja JL,Goulis J,Loglio A,Keskin O,Hansen BE,de la Revilla J,Kourikou A,Galanis K,Berg T,Esteban R,Lampertico P.The risk of hepatocellular carcinoma is decreasing after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B..Hepatology2017;66:1444-53

[101] Kim BH,Kim EY,Won YJ,Park S.Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population..J Gastroenterol Hepatol2017;

[102] Shim JJ,Kim JW,Kim BH.Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy..Scand J Gastroenterol2017;52:1029-36

[103] Li ZQ,Yu P,Zhang JJ,Zhang HY,Liu YM,Yan JY,Zhang Y.The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors..Clin Res Hepatol Gastroenterol2017;41:311-8

[104] Wang Y,Chen L,Bao R,Tang W,Lin L,Bao S.Randomized clinical trial: nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy..Oncotarget2016;7:58553-62 PMCID:PMC5295451

[105] Kim JH,Kim K,Gwak GY,Choi MS,Koh KC.Lamivudine versus entecavir for newly diagnosed hepatitis B virus-related hepatocellular carcinoma..Gut Liver2016;10:939-47 PMCID:PMC5087934

[106] Yuan P,Qian Y.Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: an updated meta-analysis..Can J Gastroenterol Hepatol2016;2016:5234969

[107] Xia BW,Wang J,He XD.Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis..Clin Res Hepatol Gastroenterol2015;39:458-68

[108] Sun P,Cheng X,Zheng Q.Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis..PLoS One2014;9:e102761 PMCID:PMC4109946

[109] Yeh YC,Kuo RN,Shau WY,Lai MS.Association of adjuvant antiviral therapy with risk of cancer progression and deaths in patients with hepatitis-B-virus-related hepatocellular carcinoma following curative treatment: a nationwide cohort study..PLoS One2014;9:e102051 PMCID:PMC4098996

[110] Fung J,Seto WK.Emerging drugs for the treatment of hepatitis B..Expert Opin Emerg Drugs2016;21:183-93